Pfizer and J&J end development of Alzheimer's drug
NEW YORK (AP) - Pfizer Inc. and Johnson & Johnson said Monday they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.
The companies hoped their drug bapineuzumab would slow the decline in physical and mental function for patients with Alzheimer's. However the drug did not work better than a placebo in two late-stage trials in patients who had mild to moderate Alzheimer's disease. Johnson & Johnson made a big bet on bapineuzumab in 2009, agreeing to invest up to $1.5 billion initially.
The drug is designed to prevent the buildup of plaque in the brain. Current treatments for Alzheimer's can only temporarily ease symptoms of the disease, which include increasing memory loss, confusion, wandering and aggression.
The two companies said July 23 that the drug had failed in a different trial. All other studies are now being discontinued, and Johnson & Johnson, based in New Brunswick, N.J., said it will take a charge of $300 million to $400 million in the third quarter.
Dublin-based Elan Corp. PLC, which licensed the drug to Johnson & Johnson in 2009, said it will take a $117.3 million charge of its own.
Shares of Elan lost 9.4 percent, or $1.06, to $10.19 in after-hours trading. Shares of New York-based Pfizer lost 2.9 percent, or 71 cents, to $23.55. Johnson & Johnson stock edged down by 67 cents to $68.17.
In the latest trial, bapineuzumab was tested on about 1,300 patients who lacked a gene that is associated with a greater risk of Alzheimer's. Last month the companies said the drug also didn't work on patients who do have that gene. Pfizer and Johnson & Johnson were running two other late-stage trials as part of a very large testing program for the drug.
Worldwide, about 35 million people already have dementia, of which Alzheimer's is the most common type. In the U.S., about 5 million have Alzheimer's. Finding a drug that could at least slow the disease has become a sort of Holy Grail in the pharmaceutical industry. A successful medicine would be guaranteed to generate billions in annual sales, given the world's aging population.
The companies hoped their drug bapineuzumab would slow the decline in physical and mental function for patients with Alzheimer's. However the drug did not work better than a placebo in two late-stage trials in patients who had mild to moderate Alzheimer's disease. Johnson & Johnson made a big bet on bapineuzumab in 2009, agreeing to invest up to $1.5 billion initially.
The drug is designed to prevent the buildup of plaque in the brain. Current treatments for Alzheimer's can only temporarily ease symptoms of the disease, which include increasing memory loss, confusion, wandering and aggression.
The two companies said July 23 that the drug had failed in a different trial. All other studies are now being discontinued, and Johnson & Johnson, based in New Brunswick, N.J., said it will take a charge of $300 million to $400 million in the third quarter.
Dublin-based Elan Corp. PLC, which licensed the drug to Johnson & Johnson in 2009, said it will take a $117.3 million charge of its own.
Shares of Elan lost 9.4 percent, or $1.06, to $10.19 in after-hours trading. Shares of New York-based Pfizer lost 2.9 percent, or 71 cents, to $23.55. Johnson & Johnson stock edged down by 67 cents to $68.17.
In the latest trial, bapineuzumab was tested on about 1,300 patients who lacked a gene that is associated with a greater risk of Alzheimer's. Last month the companies said the drug also didn't work on patients who do have that gene. Pfizer and Johnson & Johnson were running two other late-stage trials as part of a very large testing program for the drug.
Worldwide, about 35 million people already have dementia, of which Alzheimer's is the most common type. In the U.S., about 5 million have Alzheimer's. Finding a drug that could at least slow the disease has become a sort of Holy Grail in the pharmaceutical industry. A successful medicine would be guaranteed to generate billions in annual sales, given the world's aging population.
Do not like this blog machine that KOMO is using!!
Article in yahoo concerning Diacetyl and its effects in yahoo. Can't seem to copy and paste URL's into the verbage, anyone know why??
This is really disappointing..
 @Mr. H What is?
 @Mr. H I agree. There is a lot of good people that dont deserve what Alzheimers does to their minds. Maybe its not a total loss between these two companies with their data?
 @DarkRenegade The failure to demonstrate efficacy only has value in that this particular approach (pathway + medication) can be shelved. Expensive shelving.
Â
This is why a successful drug costs over $1B to develop.Â